InsiderTradr

Medigen Biotechnology Corp. (3176.TWO)

Taipei Exchange · TWD · Healthcare · Biotechnology

NT$33.40 (+0.15%) as of

Key statistics

Market cap
4.65B
EPS (TTM)
-1.82
Dividend yield
0.00%
52-week range
28.20 – 43.60
Beta
0.29
Revenue (TTM)
1.27B
Profit margin
-19.89%
Volume
192.28k

About Medigen Biotechnology Corp.

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1990 and is headquartered in Taipei, Taiwan.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Taipei, Taiwan

medigen.com.tw

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks